GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • BASEL, Switzerland, June 30- Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company's head of pharmaceuticals said on Tuesday. How the product should be priced, however, is a dilemma for Novartis, since the company wants to reach as many patients as possible and it knows...

  • June 29- Filitsa Galani, who runs a pharmacists on the island of Salamina, near Athens, had her first taste of life under Greece's new capital controls regime when she spoke to suppliers on Monday and heard they were restricting orders. Sunday's decision to impose capital controls, blocking transfers out of Greece after a flood of withdrawals, had been expected...

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 29- Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. Results from another trial...

  • Switzerland's Novartis buys US biotech firm Spinifex Monday, 29 Jun 2015 | 4:03 AM ET

    BERLIN— Swiss drug manufacturer Novartis says it is buying Spinifex Pharmaceuticals, a U.S.-based biotechnology company that specializes in developing treatments for chronic pain. Novartis didn't disclose financial details Monday of the agreement to buy privately held Spinifex, which has its headquarters in Stamford, Connecticut, and an office in...

  • BASEL, Switzerland, June 29- Swiss drugmaker Novartis AG boosted its presence in pain management on Monday by agreeing to buy U.S.-Australian biotech firm Spinifex Pharmaceuticals, the companies said in separate statements on Monday. Spinifex said Novartis was paying $200 million upfront and Spinifex shareholders could get further payments based on...

  • June 26- Animal health drugmaker Aratana Therapeutics Inc said its experimental appetite-stimulating drug was found effective in dogs in a pivotal study. The company said it plans to submit the results to the U.S. Food and Drug Administration as it seeks marketing approval, and expects to start commercializing the drug in 2016.. The Kansas City- based...

  • June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Shares of Zoetis, whose pipeline includes medicines and vaccines for pets and livestock, were up 2 percent at $56.65 in extended trading. The decision came a month after Bill Ackman's Pershing...

  • Eli Lilly and Cree are big market movers Thursday, 25 Jun 2015 | 4:46 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Eli Lilly and Co., up $2.54 to $84.80. Lindsay Corp., up $7.08 to $89.70.

  • Valeant offers to buy Zoetis - WSJ Thursday, 25 Jun 2015 | 4:30 PM ET

    June 25- Canada- based drugmaker Valeant Pharmaceuticals International Inc has approached to buy Zoetis Inc, an animal-health company, the Wall Street Journal reported. Zoetis, spun off from Pfizer Inc in 2013, was valued at $24.85 billion as of Thursday's close, according to Thomson Reuters data. It was not clear what Zoetis's reaction to the approach was, if any,...

  • Health care stocks surge as investors cheer ruling Thursday, 25 Jun 2015 | 10:42 AM ET
    Protesters outside the Supreme Court on March 4, 2015.

    See how major health care industry stocks are responding to the Supreme Court's Obamacare ruling.

  • INDIANAPOLIS— Eli Lilly received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug. Shares of the Indianapolis drugmaker climbing in premarket trading. Alimta brought in $2.79 billion in sales globally last year as...

  • TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. Perrigo's shares have been listed on TASE since it acquired Israeli...

  • Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Wednesday, 24 Jun 2015 | 9:07 AM ET

    TEL AVIV, June 24- Drugmaker Mylan NV's chief financial officer John Sheehan said on Wednesday the company would like to join the Tel Aviv Stock Exchange if it succeeds in buying Perrigo Co.. Mylan, which has its primary listing in the United States, has offered to acquire Perrigo for $34 billion. "Mylan believes that the Israeli market is important to Mylan and the...

  • Kite Pharma CEO: Targeting cancer cells Wednesday, 24 Jun 2015 | 7:52 AM ET
    Kite Pharma CEO: Targeting cancer cells

    Arie Belldegrun, Kite Pharma CEO, discusses the future of immunotherapy and its collaboration to develop cancer T-cell therapies.

  • Inside Kite Pharma's 100% run Wednesday, 24 Jun 2015 | 7:51 AM ET
    Inside Kite Pharma's 100% run

    CNBC's Meg Tirrell takes a look at what's driving shares of Kite Pharma higher, as the biotech company announces it is joining forces with Bluebird to collaborate on cancer T-cell therapies.

  • June 24- Business sentiment at Asia's top companies was little changed in the second quarter from the first, with the building sector reporting the most optimistic outlook, followed by the food sector's most upbeat reading in two years. The Thomson Reuters/ INSEAD Asian Business Sentiment Index, representing the six-month outlook at 117 firms, was 70 for the...

  • Genetic based testing, growth area for us: DGX CEO Tuesday, 23 Jun 2015 | 1:15 PM ET
    Genetic based testing, growth area for us: DGX CEO

    Steve Rusckowski, Quest Diagnostics CEO, sits down with CNBC's Meg Tirrell for an exclusive interview.

  • Great time for Boston Scientific: CEO Tuesday, 23 Jun 2015 | 12:32 PM ET
    Great time for Boston Scientific: CEO

    CNBC's Meg Tirrell sits down with Michael Mahoney, Boston Scientific CEO, for an exclusive interview.

  • Excited about new product: Medtronic CEO Tuesday, 23 Jun 2015 | 11:39 AM ET
    Excited about new product: Medtronic CEO

    CNBC's Meg Tirrell sits down with Omar Ishrak, Medtronic CEO, for an exclusive interview to discuss the company's product pipeline and business strategy.